In patients with NMOSD, there is a decline in executive function in terms of sustained attention, phonological verbal fluency, and working memory. Neuropsychological assessments in the clinical ...

"[There is] an opportunity within the healthcare space to create tools within the electronic medical record system that more effectively link symptoms and their duration, diagnostic study results, and ...

– First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks – – First ...

Elevated EBNA-1 peptide antibody titers were substantially more prevalent in RRMS than in MOGAD, NMOSD, other inflammatory neurologic diseases, other neurologic diseases, or healthy controls.

NMOSD is a unifying term for neuromyelitis optica (NMO) and related syndromes. NMOSD is a rare, severe, relapsing, neuroinflammatory autoimmune disease that attacks the optic nerve, spinal cord, brain ...

-- New data links UPLIZNA treatment to fewer severe attacks and reduced levels of key disease-related biomarkers versus placebo -- Treatment of NMOSD aims to reduce acute attacks associated with the ...

A curative treatment for NMOSD does not currently exist. The main treatment goals are remission, long-term stabilization of disease course by means of relapse prevention and residual symptom relief.

Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

Findings showed treatment with Ultomiris resulted in a statistically significant and clinically meaningful reduction in the risk of relapse compared with the external placebo arm. The Food and Drug ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that multiple UPLIZNA analyses will be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, April ...